Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Leonid Shamban

Gastroenterology Saint Clair Shores, MI Doctor of Osteopathy

NPI 1225398431 CMS profile 100632

28963 Little Mack Ave Ste 101, Saint Clair Shores, MI 48081

Open in the dashboard

General payments

$18,293

726 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Leonid Shamban of Saint Clair Shores, MI is reported in the CMS Open Payments database as having received $18,293 across 726 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,860 153
2024 General $3,172 137
2023 General $5,012 160
2022 General $2,307 121
2021 General $2,231 49
2020 General $405 23
2019 General $1,305 83

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Leonid Shamban
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Leonid Shamban were reported at $3,860. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Leonid Shamban Gastroenterology median Middle half National median
2019 $1,305 $417 $126–$1,100 $163
2020 $405 $224 $74–$624 $114
2021 $2,231 $352 $106–$1,054 $132
2022 $2,307 $448 $129–$1,270 $149
2023 $5,012 $533 $150–$1,390 $160
2024 $3,172 $605 $160–$1,606 $164
2025 $3,860 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $3,480 156 payments
  2. Janssen Biotech, Inc. $2,393 114 payments
  3. Janssen Scientific Affairs, LLC $2,098 8 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $1,622 91 payments
  5. RedHill Biopharma Inc. $1,336 2 payments
  6. Celgene Corporation $1,167 62 payments
  7. Gilead Sciences, Inc. $1,045 48 payments
  8. Pfizer Inc. $584 40 payments
  9. Salix Pharmaceuticals, a division of Bausch Health US, LLC $506 27 payments
  10. Regeneron Healthcare Solutions, Inc. $467 23 payments
  11. Other $3,596 155 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $14,763 717 payments
  2. Consulting Fee $2,913 2 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $316 3 payments
  4. Education $302 4 payments
Products named General payments · program years 2019–2025
  1. STELARA $3,358 81 payments
  2. TREMFYA $2,959 45 payments
  3. RINVOQ $1,604 65 payments
  4. ZEPOSIA $1,370 63 payments
  5. Talicia $1,336 2 payments
  6. ENTYVIO $1,023 59 payments
  7. SKYRIZI Immunology $905 38 payments
  8. LINZESS $862 48 payments
  9. SKYRIZI Immunology $685 23 payments
  10. CREON $456 38 payments
  11. Other $7,170 373 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 19 drugs

Part D claims

941

Median for Gastroenterology: 569

Drug cost

$2,726,855

Median for Gastroenterology: $104,976

Branded share of claims

25%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Stelara Ustekinumab Brand 97 $2,568,608
Xifaxan Rifaximin Brand 21 $61,319
Linzess Linaclotide Brand 38 $39,359
Zenpep Lipase/Protease/Amylase Brand 12 $23,856
Mesalamine Generic 37 $12,012
Rabeprazole Sodium Generic 162 $10,472
Omeprazole Generic 249 $3,227
Budesonide Ec Budesonide Brand 12 $1,786
Famotidine Generic 134 $1,563
Sucralfate Generic 12 $1,435

The 10 drugs with the highest cost, of 19 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 46 billing codes

Paid by Medicare

$230,417

Of which drugs: $140,397

Medicare patients

383

Average age 72

Services billed

9,518

190 women, 193 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 45%
Ischemic heart disease 38%
Diabetes 35%
Chronic kidney disease 31%
Heart failure 25%
COPD 25%
Depression 25%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, vedolizumab, 1 mg J3380 Office 11 7,200 $125,318

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 28 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
STELARA
  • Janssen Biotech, Inc. $359
  • Janssen Scientific Affairs, LLC $18
$377 97 —
TREMFYA
  • Janssen Biotech, Inc. $374
$374 — —
SKYRIZI
  • AbbVie, Inc. $317
$317 — —
RINVOQ
  • AbbVie, Inc. $290
$290 — —
ENTYVIO
  • Takeda Pharmaceuticals U.S.A., Inc. $191
$191 — 7,200

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 28 with Patron

Records

726 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record